{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:42:14Z","timestamp":1786653734536,"version":"build-2736575974"},"reference-count":9,"publisher":"SLACK, Inc.","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmic Surg Lasers Imaging Retina"],"published-print":{"date-parts":[[2007,9,1]]},"abstract":"\n Background and Objective:<\/jats:title>\n To evaluate the use of intravitreal pegaptanib in the treatment of choroidal neovascularization secondary to age-related macular degeneration (AMD) in treatment-na\u00efve patients.<\/jats:p>\n <\/jats:sec>\n \n Patients and Methods:<\/jats:title>\n In a consecutive, retrospective case series, treatment-na\u00efve patients with exudative AMD were treated with intravitreal pegaptanib. Intravitreal injections were typically given every 6 weeks at the discretion of the treating physician. Snellen visual acuity (VA), clinical course, and adverse events were monitored. A minimum of three pegaptanib injections were given. Retreatment criteria included persistent submacular fluid, macular edema, new macular hemorrhage, and loss of vision.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n The average change in VA for all lesions was a loss of 2.9 lines. Fifteen (14%) patients gained more than 3 lines of VA. The average number of in jections was 4.8. Ninety-two of 111 lesions were able to be categorized by size. Sixty-six patients had small lesions (< 4 disc areas) with an average change of \u22122.0 lines, and 26 had large lesions (\u2a7e 4 disc areas) with an average change of \u22125.4 lines (\n P<\/jats:italic>\n < .02). Patients with larger lesions were at greater risk for severe visual loss (\n P<\/jats:italic>\n < .01). The average follow-up was approximately 31 weeks (range: 12 to 82 weeks) after the first injection.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n Pegaptanib therapy resulted in a 2.9 average line loss in patients when all lesions were considered. Small lesions responded favorably, with 15% of patients gaining more than 3 lines of VA. Larger lesions had an increased risk of progression and poor visual outcome.<\/jats:p>\n \n [Ophthalmic Surg Lasers Imaging 2007;38:371\u2013377.]<\/jats:bold>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3928\/15428877-20070901-03","type":"journal-article","created":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T11:45:44Z","timestamp":1570448744000},"page":"371-377","source":"Crossref","is-referenced-by-count":5,"title":["Pegaptanib for Choroidal Neovascularization in Treatment-Na\u00efve Exudative Age-Related Macular Degeneration"],"prefix":"10.3928","volume":"38","author":[{"given":"Justis P.","family":"Ehlers","sequence":"first","affiliation":[{"name":"Wills Eye Institute, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Fintak","sequence":"additional","affiliation":[{"name":"Wills Eye Institute, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omesh P.","family":"Gupta","sequence":"additional","affiliation":[{"name":"Wills Eye Institute, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl D.","family":"Regillo","sequence":"additional","affiliation":[{"name":"The Retina Service"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell S.","family":"Fineman","sequence":"additional","affiliation":[{"name":"The Retina Service"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen C.","family":"Ho","sequence":"additional","affiliation":[{"name":"The Retina Service"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-4182(05)80078-X"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042760"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.05.070"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.iae.0000225766.75009.3a"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200510000-00001"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.02.027"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.10.053"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2006.03.051"}],"container-title":["Ophthalmic Surgery, Lasers and Imaging Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.healio.com\/ophthalmology\/journals\/osli\/2007-9-38-5\/%7Bd933d7c0-9764-4cba-89dc-0e0cdae72466%7D\/pegaptanib-for-choroidal-neovascularization-in-treatment-nave-exudative-age-related-macular-degeneration","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:41:41Z","timestamp":1786650101000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/15428877-20070901-03"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,1]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,9,1]]}},"alternative-id":["10.3928\/15428877-20070901-03"],"URL":"https:\/\/doi.org\/10.3928\/15428877-20070901-03","relation":{},"ISSN":["2325-8160","2325-8179"],"issn-type":[{"value":"2325-8160","type":"print"},{"value":"2325-8179","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,1]]}}}